Last Modified: July 6, 2003
Conference Dates: February 5-6, 2004
Conference Location: Geneva, Switzerland
Sponsoring Group: MSKCC, Clinique de Genolier, Imedex
Conference Web Page URL: www.imedex.com/calendars/oncology.htm
Topics Covered: Conference Summary - Participants at this meeting will learn about new ways and means to optimize chemotherapy and hormonal therapy in cancer patients. Recent progress in antiemetic agents allows long term control of nausea and vomiting, not only acute phase control. New growth factors promise an easier erythropoietic and granulocytic support, and such support can be crucial for optimal outcomes. Bisphosphonates may have a role in adjuvant therapy, along with chemotherapy and hormonal agents. Decrease of mucositis and appropriate treatment of infectious complications in outpatients with solid tumours will also be discussed.
Continuing Education: Yes
Jan 4, 2012 - Patients with human epidermal growth factor receptor 2-positive advanced breast cancer whose tumors also express hormone receptors may be less responsive to the addition of trastuzumab to chemotherapy, suggesting that hormone receptor expression has a predictive role in determining response to therapy, according to research published in the Jan. 1 issue of Cancer.
Nov 6, 2012